Research programme: CAR-T cell therapies - Juno Therapeutics
Alternative Names: Chimeric antigen receptor T cell therapies - Juno TherapeuticsLatest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator Juno Therapeutics
- Developer Bristol-Myers Squibb; Juno Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Unspecified
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Unspecified in United Kingdom (Parenteral)
- 28 Apr 2024 No recent reports of development identified for preclinical development in Unspecified in USA (Parenteral)